Skip to main content
SpringerLink
Log in

One year in—Obama's biotech scorecard

  • News Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

As healthcare reform falters, the biotech industry awaits the fate of biosimilars and tax credits. Jeff Fox reports.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Healthcare refom timeline.

Author information

Authors and Affiliations

  1. Washington DC

    Jeffrey L Fox

Authors
  1. Jeffrey L Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fox, J. One year in—Obama's biotech scorecard. Nat Biotechnol 28, 193–196 (2010). https://doi.org/10.1038/nbt0310-193

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0310-193

  • Springer Nature America, Inc.

Search

Navigation